VivoSeq
Other

Clinical Trial

0

Pipeline Programs↗

163

Active Trials↗

135

Companies Involved↗

Clinical Trial is an early-stage landscape with 0 programs across 135 companies. The most active players are Chong Kun Dang Pharmaceutical, Pfizer, Boryung Pharmaceutical Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

71/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBoryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd

0 programs

PreclinicalAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd. logo

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

0 programs

PreclinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalCanSino Biologics Inc. logo

CanSino Biologics Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

909

clinical trials

Completed523 · 58%
Unknown status159 · 17%
Recruiting72 · 8%
Not yet recruiting41 · 5%
Active, not recruiting40 · 4%
Terminated39 · 4%
Other35 · 4%

Clinical Trials

Trial Activity

909 trials

A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults
Recruiting·SSinotau Pharmaceutical Group·Phase 1·NCT07149831·6 enrolled
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05931263·104 enrolled
BCG for Therapeutic Use Phase Ⅲ Clinical Trial
Recruiting·Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. logoAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.·Phase 3·NCT06747455·438 enrolled
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Recruiting·—·N/A·NCT05391126·178 enrolled
Clinical Trial of PCV24 in Infants Aged 2-23 Months
Recruiting·SSinovac Life Sciences Co., Ltd.·Phase 1·NCT06800261·180 enrolled
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Recruiting·JJohns Hopkins University·Phase 2·NCT07059091·334 enrolled
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Recruiting·Pfizer logoPfizer·Phase 4·NCT05203172·46 enrolled
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
Recruiting·NNingbo Rongan Biological Pharmaceutical Co., Ltd.·Phase 1·NCT07021703·60 enrolled
Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD
Recruiting·BBeijing Union Pharmaceutical Factory Ltd·Phase 3·NCT06243614·410 enrolled
Clinical Trial of Microneedle Radiofrequency Combined With Oral Isotretinoin in Moderate to Severe Acne
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT06378983·100 enrolled
SB17170 Phase 1 Clinical Trial in Solid Tumors
Recruiting·SSPARK Biopharma·Phase 1·NCT05522868·50 enrolled
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT05999994·105 enrolled
A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs
Recruiting·Daewon Pharmaceutical Co., Ltd. logoDaewon Pharmaceutical Co., Ltd.·Phase 1·NCT07343245·150 enrolled
Phase I Single-blind Clinical Trial to Evaluate the Safety and Local Immune Activation of a Toll-like Receptor 5 Agonist (FLAMOD) Administered by Aerosol
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1·NCT06681402·60 enrolled
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial
Recruiting·AAnterogen Co., Ltd.·N/A·NCT06141811·104 enrolled
Page 1 of 61

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)